Evidence map›Paper›PMID 38953158›Full record

ArticleThe Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association2025

Associations between COVID-19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS-CoV-2 variants.

A Jerrod Anzalone, William H Beasley, Kimberly Murray, William B Hillegass, Makayla Schissel, Michael T Vest, Scott A Chapman, Ronald Horswell, Lucio Miele, J Zachary Porterfield and 8 more

Abstract readMulticenter Study
In one paragraph

Article in The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Associations between COVID-19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS-CoV-2 variants.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

A Jerrod AnzaloneUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0002-3212-7845
William H BeasleyUniversity of Oklahoma, Norman, Oklahoma, USA.ORCID 0000-0002-5613-5006
Kimberly MurrayMaine Health Institute for Research, Portland, Maine, USA.
William B HillegassUniversity of Mississippi Medical Center, Jackson, Mississippi, USA.ORCID 0000-0001-6428-0564
Makayla SchisselUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.
Michael T VestChristiana Care Health System, Newark, Delaware, USA.ORCID 0000-0002-3525-6095
Scott A ChapmanUniversity of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.ORCID 0000-0002-1594-1554
Ronald HorswellLouisiana State University Health Sciences Center, New Orleans, Louisiana, USA.ORCID 0000-0002-7317-7523
Lucio MieleLouisiana State University Health Sciences Center, New Orleans, Louisiana, USA.ORCID 0000-0002-5853-7287
J Zachary PorterfieldUniversity of Kentucky, Lexington, Kentucky, USA.ORCID 0000-0002-2724-9928
H Timothy BunnellNemours Children's Health, Wilmington, Delaware, USA.
Bradley S PriceWest Virginia University, Morgantown, West Virginia, USA.
Sharon PatrickWest Virginia University, Morgantown, West Virginia, USA.ORCID 0000-0001-6535-2013
Clifford J RosenMaine Health Institute for Research, Portland, Maine, USA.ORCID 0000-0003-3436-8199
Susan L SantangeloMaine Health Institute for Research, Portland, Maine, USA.ORCID 0000-0001-5576-4495
James C McClayUniversity of Missouri School of Medicine, Columbia, Missouri, USA.ORCID 0000-0002-3404-0671
Sally L HodderWest Virginia University, Morgantown, West Virginia, USA.ORCID 0000-0002-0728-5550
National COVID Cohort Collaborative (N3C) Consortium

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI JUDITH FEINBERG · 2012 to 2026
$81.0M
Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI JUDITH A JAMES · 2013 to 2026
$68.2M
Subproject Title: Clinical Research Education, Mentoring and Career Development CoreU54GM104941 · NIGMS · UNIVERSITY OF DELAWARE · PI Megan M Wenner · 2013 to 2026
$60.5M
Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI Frances E. Carr · 2017 to 2026
$51.6M
Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI ROUNDS, SHARON IRENE SMITH · 2016 to 2025
$45.0M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ZHANG, YING · 2016 to 2025
$42.8M
Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI GOMEZ-SANCHEZ, CELSO ENRIQUE · 2016 to 2025
$38.2M
CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR CollaborationU24TR002306 · NCATS · UNIVERSITY OF COLORADO DENVER · PI CHUTE, CHRISTOPHER G, EICHMANN, DAVID A. · 2017 to 2021
$28.9M
Tracking and Evaluation CoreU54GM128729 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI BASSON, MARC D. · 2018 to 2022
$20.3M
Tracking and Evaluation CoreU54GM133807 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI PORTER, JAMES T. · 2020 to 2024
$17.7M
Tracking and Evaluation CoreU54GM138062 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI SY, ANGELA U · 2021 to 2025
$15.5M
NCATS NIH HHS U24 TR002306NCATS U24 TR002306NIGMS NIH HHS U54 GM104938NIGMS NIH HHS U54GM104938NIGMS NIH HHS U54 GM104940NIGMS NIH HHS U54GM104940NIGMS NIH HHS U54 GM104941NIGMS NIH HHS U54GM104941NIGMS NIH HHS U54 GM104942NIGMS NIH HHS U54GM104942NIGMS NIH HHS U54 GM115428NIGMS NIH HHS U54GM115428NIGMS NIH HHS U54 GM115458NIGMS NIH HHS U54GM115458NIGMS NIH HHS U54 GM115516NIGMS NIH HHS U54GM115516NIGMS NIH HHS U54 GM115677NIGMS NIH HHS U54GM115677NIGMS NIH HHS U54 GM128729NIGMS NIH HHS U54GM128729NIGMS NIH HHS U54 GM133807NIGMS NIH HHS U54GM133807NIGMS NIH HHS U54 GM138062NIGMS NIH HHS U54GM138062
6 · The paper itself

Abstract

purposeTo investigate the enduring disparities in adverse COVID-19 events between urban and rural communities in the United States, focusing on the effects of SARS-CoV-2 vaccination and therapeutic advances on patient outcomes.

methodsUsing National COVID Cohort Collaborative (N3C) data from 2021 to 2023, this retrospective cohort study examined COVID-19 hospitalization, inpatient death, and other adverse events. Populations were categorized into urban, urban-adjacent rural (UAR), and nonurban-adjacent rural (NAR). Adjustments included demographics, variant-dominant waves, comorbidities, region, and SARS-CoV-2 treatment and vaccination. Statistical methods included Kaplan-Meier survival estimates, multivariable logistic, and Cox regression.

findingsThe study included 3,018,646 patients, with rural residents constituting 506,204. These rural dwellers were older, had more comorbidities, and were less vaccinated than their urban counterparts. Adjusted analyses revealed higher hospitalization odds in UAR and NAR (aOR 1.07 [1.05-1.08] and 1.06 [1.03-1.08]), greater inpatient death hazard (aHR 1.30 [1.26-1.35] UAR and 1.37 [1.30-1.45] NAR), and greater risk of other adverse events compared to urban dwellers. Delta increased, while Omicron decreased, inpatient adverse events relative to pre-Delta, with rural disparities persisting throughout. Treatment effectiveness and vaccination were similarly protective across all cohorts, but dexamethasone post-ventilation was effective only in urban areas. Nirmatrelvir/ritonavir and molnupiravir better protected rural residents against hospitalization.

conclusionsDespite advancements in treatment and vaccinations, disparities in adverse COVID-19 outcomes persist between urban and rural communities. The effectiveness of some therapeutic agents appears to vary based on rurality, suggesting a nuanced relationship between treatment and geographic location while highlighting the need for targeted rural health care strategies.

Indexed as

COVID-19Rural PopulationSARS-CoV-2Urban PopulationAdultAgedAntiviral AgentsCOVID-19 Drug TreatmentCOVID-19 VaccinesFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesUnited StatesAntiviral AgentsCOVID-19 VaccinesCOVID‐19 TherapiesMortalityNational COVID Cohort Collaborative (N3C)SARS‐CoV‐2Urban‐Rural Health

Identifiers

PMID38953158
PMCPMC11635344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.